XML 30 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Commitments and Contingencies (Tables)
 3 Months Ended
Mar. 31, 2016
Commitments and Contingencies [Abstract]  
Summary of milestone payments
Milestones Payments 
    
(1) when Company initiates a Phase 1 Clinical Trial of a licensed product $750,000 
(2) when Company initiates a Phase 2 Clinical Trial of a licensed product  750,000 
(3) when Company initiates a Phase 3 Clinical Trial of a licensed product  1,500,000 
(4) Biological License Application filing with U.S. FDA  1,750,000 
(5) First commercial sale  1,500,000 
(6) after the first $10,000,000 in net sales  1,500,000 
Schedule of future minimum obligations on the lease
For the year ending March 31, 2016 $255,448 
For the year ending March 31, 2017  199,440 
For the year ending March 31, 2018  149,580 
Total $604,468